Q. Zhang

562 total citations
27 papers, 272 citations indexed

About

Q. Zhang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Q. Zhang has authored 27 papers receiving a total of 272 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Q. Zhang's work include HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Q. Zhang is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Q. Zhang collaborates with scholars based in China, Taiwan and Switzerland. Q. Zhang's co-authors include Jin Shi, Xinmei Kang, Xiao‐Jun Huang, Jianqun Ma, Dabei Tang, Yuwei Deng, W. Li, Pingzhang Tang, Monika Patre and Ezra E.W. Cohen and has published in prestigious journals such as Annals of Oncology, Life Sciences and European Journal of Cancer.

In The Last Decade

Q. Zhang

25 papers receiving 256 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Q. Zhang China	8	164	110	73	54	50	27	272
T Sugiura Japan	8	242 1.5×	119 1.1×	48 0.7×	25 0.5×	195 3.9×	14	416
Von G. Samedi United States	9	106 0.6×	36 0.3×	97 1.3×	57 1.1×	95 1.9×	19	322
Regina Courtney United States	10	97 0.6×	45 0.4×	22 0.3×	99 1.8×	195 3.9×	17	458
S. L. Graziano United States	5	87 0.5×	125 1.1×	7 0.1×	58 1.1×	141 2.8×	8	283
Fundagül Andiç Türkiye	10	52 0.3×	68 0.6×	48 0.7×	5 0.1×	69 1.4×	22	347
Gail L. Shaw United States	11	159 1.0×	100 0.9×	59 0.8×	108 2.0×	138 2.8×	24	394
M. Navarro Spain	8	190 1.2×	50 0.5×	46 0.6×	61 1.1×	88 1.8×	16	327
Xiaohui Yuan China	11	74 0.5×	40 0.4×	16 0.2×	12 0.2×	178 3.6×	25	319
Julie Bélanger Canada	9	174 1.1×	63 0.6×	74 1.0×	32 0.6×	110 2.2×	9	381
Terrilea Burnett United States	10	170 1.0×	33 0.3×	194 2.7×	65 1.2×	82 1.6×	13	396

Countries citing papers authored by Q. Zhang

Since Specialization

Citations

This map shows the geographic impact of Q. Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Q. Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Q. Zhang more than expected).

Fields of papers citing papers by Q. Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Q. Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Q. Zhang. The network helps show where Q. Zhang may publish in the future.

Co-authorship network of co-authors of Q. Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Q. Zhang. A scholar is included among the top collaborators of Q. Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Q. Zhang. Q. Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Feng, Jie, et al.. (2025). CHI3L1 promotes macrophage pyroptosis in ulcerative colitis via the BCAT1/NF-κB axis. Life Sciences. 384. 124108–124108.

Im, Seock‐Ah, Shoei‐Shen Wang, Yen‐Shen Lu, et al.. (2024). PS3-1 Dato-DXd vs. chemotherapy for patients with inoperable/metastatic HR+/HER2− breast cancer: TROPION-Breast01 Asian subset. Annals of Oncology. 35. S1314–S1314.

Liu, Ming-wei, Xiaoguang Wu, Q. Zhang, et al.. (2024). Targeting GPR39 in structure-based drug discovery reduces Ang II-induced hypertension. Communications Biology. 7(1). 1 indexed citations

Zhang, Q., et al.. (2023). Analysis of the Efficacy and Safety of Coronary Catheterization through Distal Transradial Access: A Single-Center Data. Cardiovascular Therapeutics. 2023. 1–6. 3 indexed citations

Shao, Zhimin, Q. Zhang, Ning Liao, et al.. (2023). 107P Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: Abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer. ESMO Open. 8(1). 101331–101331. 1 indexed citations

Zhang, Q., Jing Wang, Quchang Ouyang, et al.. (2023). 418P Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer. Annals of Oncology. 34. S358–S358. 4 indexed citations

Xu, Binghe, W. Li, Q. Zhang, et al.. (2022). 196P Final analysis of PUFFIN: A phase III, randomised double-blind, placebo (Pla)-controlled study of pertuzumab, trastuzumab and docetaxel (PHD) for Chinese patients (pts) with previously untreated HER2-positive locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology. 33. S217–S218. 2 indexed citations

Jiménez, M. Martín, Elgene Lim, Amit Bardia, et al.. (2022). 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Annals of Oncology. 33. S633–S634. 43 indexed citations

Xu, Binghe, Min Yan, W. Li, et al.. (2022). LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial. Annals of Oncology. 33. S1387–S1387. 14 indexed citations

10.

Shen, Lin, Yi‐Long Wu, Ying Yuan, et al.. (2020). 552P Safety and efficacy of long-term exposure (LTE) to tislelizumab in Chinese patients with advanced solid tumours. Annals of Oncology. 31. S478–S479. 1 indexed citations

11.

Shen, Lin, J. Li, Nong Xu, et al.. (2020). 1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study. Annals of Oncology. 31. S909–S909. 7 indexed citations

12.

Guo, Ye, Myung‐Ju Ahn, Anthony T.�C. Chan, et al.. (2019). Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Annals of Oncology. 30(11). 1831–1839. 40 indexed citations

13.

Shen, Lin, Nong Xu, Baocai Xing, et al.. (2019). A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas. Annals of Oncology. 30. v516–v516. 4 indexed citations

14.

Xu, Binghe, Q. Zhang, Tao Sun, et al.. (2019). First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer. Annals of Oncology. 30. ix185–ix185. 3 indexed citations

15.

Guo, Ye, Yifeng Luo, Q. Zhang, et al.. (2018). First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial. Annals of Oncology. 29. ix176–ix176. 1 indexed citations

16.

Blayney, Douglas W., Stephan Ogenstad, Yuankai Shi, et al.. (2018). P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients. Journal of Thoracic Oncology. 13(10). S461–S461. 2 indexed citations

17.

Jiang, Zefei, W. Li, Xin Hu, et al.. (2018). Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer. Annals of Oncology. 29. viii709–viii709. 4 indexed citations

18.

Shi, Yuankai, Q. Zhang, Xiao-Feng Han, et al.. (2018). First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). Annals of Oncology. 29. ix88–ix88. 3 indexed citations

19.

Wu, Yi‐Long, Jun Zhao, Q. Zhang, et al.. (2018). P2.04-29 Preliminary Results With Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S741–S742. 1 indexed citations

20.

Kang, Xinmei, et al.. (2010). Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. Canadian Medical Association Journal. 182(17). 1857–1862. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact